Big Pharma’s ad men may need their own prescriptions after President Trump’s latest move.
On Tuesday, the president signed an executive memorandum directing Health and Human Services Secretary Robert F. Kennedy Jr. to force pharmaceutical companies into full disclosure in their consumer advertising. The message is simple: if you’re going to hawk prescription drugs on TV, you’re going to tell the whole truth—including the full list of risks and side effects.
For decades, Americans have been bombarded by glossy ads promising miracle treatments, always accompanied by a rushed disclaimer rattling off a handful of dangers.
What most viewers don’t realize is that those ads rely on an “adequate provision loophole,” which allows companies to list only a portion of risks, so long as they provide a website or 1-800 number for the rest. How many people dial those numbers? How many chase down the fine print? Very few. The result is a public left underinformed about drugs that could alter their lives—or shorten them.
MAHA🇺🇸
President Trump has signed a memorandum directing @SecKennedy to ensure transparency and accuracy in direct-to-consumer prescription drug advertising and @DrMakaryFDA to enforce the prescription drug advertising provisions of the Federal Food, Drug, and Cosmetic Act. pic.twitter.com/SxyIre2fBB
— The White House (@WhiteHouse) September 9, 2025
Trump’s order is designed to close that gap. Kennedy is directed to ensure “transparency and accuracy in direct-to-consumer prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug.” At the same time, the FDA commissioner is being told to enforce the Federal Food, Drug, and Cosmetic Act’s advertising provisions with teeth, ensuring that ads are truthful and not misleading.
The consequences will be immediate. Television and digital ads will grow longer, more expensive, and less effective at glossing over the dangers. Executives who built their fortunes on slick marketing campaigns are now staring at the prospect of disclosure-heavy commercials that could scare off consumers rather than entice them. For patients, however, the calculus changes—transparency becomes the priority, not shareholder value.
It’s also a political moment worth noting. Kennedy, once a fierce independent critic of pharmaceutical giants and direct-to-consumer advertising, is now being empowered by Trump to deliver on promises he made before joining the administration. For a cabinet member still fending off calls for resignation, this is the president’s public stamp of approval—a way of signaling that Kennedy’s long war with Big Pharma has the White House behind it.
The crackdown dovetails with the administration’s Make America Healthy Again Commission report, which singled out abuses not just from drug ads but from online influencers and telehealth operators. Trump’s approach is consistent: consumers first, corporate spin last.
As the president himself said: “I’ve [never] been loyal to the special interests; I have been loyal to our patients and our people that need drugs—prescription drugs—and devoted myself completely to fighting for the American people.”
